BeOne Medicines (BEIGF) Net Cash Flow (QoQ) (2015 - 2026)
Analysis
BeOne Medicines (BEIGF) Net Cash Flow (QoQ) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.48 Bn | 625.73 Bn | 17.26 Bn |
| 2 | AbbVie | 442.74 Bn | 436.17 Bn | 12.70 Bn |
| 3 | Merck | 366.39 Bn | 359.25 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn |
| 5 | Pfizer | 158.80 Bn | 147.10 Bn | 10.94 Bn |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 81.51% |
| Mar 31, 2026 | -52.84% |
| Dec 31, 2025 | -63.79% |
| Sep 30, 2025 | 466.57% |
| Jun 30, 2025 | 307.83% |
| Mar 31, 2025 | -386.05% |
| Dec 31, 2024 | -134.20% |
| Sep 30, 2024 | 136.57% |
| Jun 30, 2024 | 48.44% |
| Mar 31, 2024 | -666.82% |
| Dec 31, 2023 | 118.41% |
| Sep 30, 2023 | -468.60% |
| Jun 30, 2023 | 82.48% |
| Mar 31, 2023 | 12.16% |
| Dec 31, 2022 | -43.30% |
| Sep 30, 2022 | -204.22% |
| Jun 30, 2022 | 797.63% |
| Mar 31, 2022 | -101.25% |
| Dec 31, 2021 | 849.29% |
| Sep 30, 2021 | -199.54% |